|
Restrictive drug policies often cause schizophrenic patients to discontinue medication
April 01, 2008Policies requiring authorization before physicians can prescribe newer medications to schizophrenic patients may be counter-productive. According to a new study, patients in Maine's Medicaid program who found themselves in this situation were 29% more likely to stop or disrupt medication use than patients not subject to the policy. In addition, although the policy was originally designed to cut costs, government savings were minimal at best.
These findings are reported online in Health Affairs.
The study, led by investigators from Harvard Medical School's Department of Ambulatory Care and Prevention, looked at Maine Medicaid beneficiaries with schizophrenia on antipsychotic drugs before, during, and after a policy that required patients to use an authorized medication (step treatment) before they were allowed to use drugs not on the preferred list. They were compared to similar beneficiaries in New Hampshire, where there was no prior authorization regulation. The Maine policy was replaced by a provider education program after less than a year.
Study data indicated that the original Maine policy disrupted essential antipsychotic treatment for vulnerable patients with schizophrenia, with minimal or no cost savings.
"This study calls into question the effectiveness of many similar policies throughout the country," says Stephen Soumerai, Harvard Medical School professor and senior author on the study. "Getting prior authorization requires paperwork and is time-consuming, so physicians may tend to switch to prescribing preferred medications even if they have concerns about the appropriateness of the medication for a specific patient." However, as medication choice is restricted, more patients discontinue treatment.
Previous studies have shown that gaps in antipsychotic medication use are likely to result in recurrence of psychotic episodes and higher hospitalization rates and costs for these patients.
Schizophrenia is a disabling and costly illness that afflicts approximately one percent of the US population, or three million people. Without antipsychotic treatment, about 80% of patients will have a serious recurrence of their illness within a year. The study investigators believe that while there is a legitimate place for prior authorization and step treatment policies for some medications, patients with chronic mental illness are put at particular risk of receiving inadequate treatment.
"Given the tremendous variation in individual responses to these drugs as well as the devastating impact of treatment disruptions on schizophrenic patients, a policy that pushes all patients toward a limited number of preferred drugs may do more harm than good," says Dr. Soumerai. "It would be much better to focus on ensuring that antipsychotic drugs are prescribed for evidence-based reasons and that preferred drugs are prescribed only to patients who can benefit from them."
Harvard Medical School
Study data indicated that the original Maine policy disrupted essential antipsychotic treatment for vulnerable patients with schizophrenia, with minimal or no cost savings.
"This study calls into question the effectiveness of many similar policies throughout the country," says Stephen Soumerai, Harvard Medical School professor and senior author on the study. "Getting prior authorization requires paperwork and is time-consuming, so physicians may tend to switch to prescribing preferred medications even if they have concerns about the appropriateness of the medication for a specific patient." However, as medication choice is restricted, more patients discontinue treatment.
Previous studies have shown that gaps in antipsychotic medication use are likely to result in recurrence of psychotic episodes and higher hospitalization rates and costs for these patients.
Schizophrenia is a disabling and costly illness that afflicts approximately one percent of the US population, or three million people. Without antipsychotic treatment, about 80% of patients will have a serious recurrence of their illness within a year. The study investigators believe that while there is a legitimate place for prior authorization and step treatment policies for some medications, patients with chronic mental illness are put at particular risk of receiving inadequate treatment.
"Given the tremendous variation in individual responses to these drugs as well as the devastating impact of treatment disruptions on schizophrenic patients, a policy that pushes all patients toward a limited number of preferred drugs may do more harm than good," says Dr. Soumerai. "It would be much better to focus on ensuring that antipsychotic drugs are prescribed for evidence-based reasons and that preferred drugs are prescribed only to patients who can benefit from them."
Harvard Medical School
Antipsychotic News and Current Antipsychotic Events RSSViolence declines with medication use in some with schizophrenia
Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center.
Short-term use of antipsychotics in older adults with dementia linked to serious adverse events
Older adults with dementia who receive short-term courses of antipsychotic medications are more likely to be hospitalized or die than those who do not take the drugs, according to a report in the May 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Hopkins researchers discover new link to schizophrenia
Neuroscientists at Johns Hopkins have discovered that mice lacking an enzyme that contributes to Alzheimer disease exhibit a number of schizophrenia-like behaviors.
Lack of motivation in schizophrenia linked to brain chemical imbalance
A study of patients with psychotic illnesses such as schizophrenia suggests an alternative explanation for why many sufferers lack motivation. The research is described today BioMed Central's journal BMC Psychiatry.
First do no harm? UH prof taking opposite approach to treat asthma
One month of tough breathing may help asthma sufferers breathe easier in the long run, according to research from one University of Houston professor.
Treatment With An Antipsychotic Drug Found To Cause Changes In Metabolism Earlier Than Expected
Schizophrenia is a complex type of psychotic mental illness characterized by thoughts that are uncoupled from reality.
Stanford researcher criticizes FDA plans to reduce oversight of off-label drug use
Proposed guidelines from the U.S. Food and Drug Administration would allow companies to market more drugs for unapproved uses and are a step in the wrong direction, said a researcher from the Stanford University School of Medicine.
Comparison of antipsychotic treatments in adolescents with schizophrenia
There is a wealth of scientific literature available on the treatment of adults diagnosed with schizophrenia. However, there is a paucity of data to guide the treatment of children and adolescents with schizophrenia.
Siblings of schizophrenia patients display subtle shape abnormalities in brain
Subtle malformations in the brains of patients with schizophrenia also tend to occur in their healthy siblings, according to investigators at the Silvio Conte Center for the Neuroscience of Mental Disorders at Washington University School of Medicine in St. Louis.
Weight gain induced by antipsychotic drugs can be avoided
A research team from Université Laval's Faculty of Medicine and Robert-Giffard Hospital has demonstrated that weight gain induced by the use of antipsychotic drugs-which in extreme cases can be as high as 30 kilos in only one month-can be avoided through a specially designed weight control program.
More Antipsychotic News Articles
| © 2008 BrightSurf.com |